Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation

NCT00064246 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00064246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00064246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2003
Completion date
Not reported
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post-transplant lymphoproliferative disorder, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, waldenström macroglobulinemia